REAL‐WORLD OUTCOMES WITH NOVEL THERAPIES IN R/R DLBCL

Introduction: Outcomes have historically been poor for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Despite an increase in approved R/R DLBCL treatment options, clinical outcomes of these therapies remain less certain. Novel treatments include chimeric antigen receptor T-cell (CAR T) therapy, polatuzumab vedotin plus bendamustine and rituximab (pola-BR), tafasitamab lenalidomide (tafa-len), loncastuximab (lonca), selinexor. This study examined real-world novel therapies. Methods: US patient data from the COTA electronic health records database (2010–2021) were used this retrospective study. Patients had a diagnosis after 1/1/2010, ≥1 prior line systemic antineoplastic therapy (including anti-CD20 antibody), any receiving variations pola-BR or tafa-len regimens included. included overall response rate (ORR), complete (CR) rate, median progression-free survival (mPFS), (mOS). analyzed those treated following CAR T exposure. Results: A total 175 (median age 63 y, 60.6% male, 2 therapies); 29.1% international prognostic index score ≥3, 61.7% stage III/IV disease, 65.7% primary refractory disease. 73, 69, 27 T, pola-BR, regimens, respectively. Only 6 lonca 0 received Among 169 2L+ setting tafa-len, CR was 11.1%, 18.8%, 52.1%, respectively (Table). 112 3L+ 10.0%, 13.5%, 41.8%, 18% agent exposure ORR 19.1%, 4.8%, mPFS mOS 1.4 mo 2.3 mo, Conclusions: suboptimal, worse as advance through lines therapy. are particularly when agents Encore Abstract—previously submitted to ASCO 2023 The research funded by: Genmab A/S AbbVie Keywords: aggressive non-Hodgkin lymphoma, cancer disparities, combination Conflicts interests pertinent abstract J. Crombie Consultant advisory role Karyopharm, Incyte, MorphoSys, Kite, ADC Therapeutics, Research funding: AbbVie, Bayer, Merck, Genentech/Roche M. Jun Employment leadership position: T. Wang A. Mutebi Chibber R. Kamalakar Ukropec Blaedel Kalsekar